Search for a command to run...
<h3>Background and Importance</h3> Ibrutinib is a Bruton tyrosine kinase inhibitor, while venetoclax is a selective inhibitor of the anti-apoptotic protein B-cell lymphoma 2. The combination of ibrutinib and venetoclax (I+V) is approved for first-line treatment in adults with chronic lymphocytic leukaemia (CLL). The complementary mechanism of action is based on ibrutinib mobilising leukaemic cells from lymph nodes to peripheral blood, where they are susceptible to venetoclax-induced apoptosis. The I+V regimen consists of three 28-day cycles of ibrutinib monotherapy, followed by the addition of venetoclax from cycle four onwards, using a recommended dose ramp-up schedule. Treatment duration is fixed at 15 cycles (three of ibrutinib alone + 12 of I+V). <h3>Aim and Objectives</h3> Given the limited availability of real-world data, this study aimed to evaluate response outcomes of I+V in clinical practice. <h3>Material and Methods</h3> A prospective analysis was conducted on patients with CLL initiating I+V therapy across four hospitals between May 2023-August 2025. All patients meet treatment criteria as per the International Workshop on Chronic Lymphocytic Leukaemia (iwCLL2018). Responses were evaluated every 3 months according to iwCLL2018 criteria, incorporating clinical, haematological, radiological, and minimal residual disease assessments. Responses were categorised as complete remission (CR), partial remission (PR), stable disease (SD), or progressive disease (PD). <h3>Results</h3> Seventeen patients were included, with a median age of 66.5 years (range 43–84); 43.8% were over 70-years-old. Immunoglobulin heavy chain variable region mutation status was mutated in 31.25% of cases. At the most recent evaluation 56.25% (n=9) achieved CR, 12.5% (n=2) achieved PR, one patient had SD, and one progressed, developing Richter’s transformation. At the study cut-off date, it was not possible to assess the response in the two remaining patients, as the follow-up time is insufficient. Among those who achieved CR, 33.3% reached it within 3 months from the start, 22.2% at 6 months, 22.2% at 12 months, 11.11% at 15 months, and 11.11% at 18 months. <h3>Conclusion and Relevance</h3> The I+V regimen demonstrated high rates of complete and partial remission, consistent with clinical trial data regarding deep responses, minimal residual disease negativity, and durable survival outcomes. Ongoing follow-up will provide further insights upon treatment completion. <h3>Conflict of Interest</h3> No conflict of interest